Page last updated: 2024-09-04

vatalanib and imatinib

vatalanib has been researched along with imatinib in 9 studies

Compound Research Comparison

Studies
(vatalanib)
Trials
(vatalanib)
Recent Studies (post-2010)
(vatalanib)
Studies
(imatinib)
Trials
(imatinib)
Recent Studies (post-2010) (imatinib)
27642982360157

Protein Interaction Comparison

ProteinTaxonomyvatalanib (IC50)imatinib (IC50)
Chain A, PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABLMus musculus (house mouse)0.1
Aurora kinase AHomo sapiens (human)4.3
Solute carrier family 22 member 2Homo sapiens (human)4.2
Bile salt export pumpHomo sapiens (human)10
Tyrosine-protein kinase ABL1Homo sapiens (human)0.6804
Tyrosine-protein kinase ABL1Mus musculus (house mouse)0.3704
Proto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)2.784
Epidermal growth factor receptorHomo sapiens (human)0.0001
Carbonic anhydrase 2Homo sapiens (human)0.372
Receptor tyrosine-protein kinase erbB-2Homo sapiens (human)0.0001
Platelet-derived growth factor receptor betaMus musculus (house mouse)0.3
Tyrosine-protein kinase LckHomo sapiens (human)0.2667
Cyclin-dependent kinase 1Homo sapiens (human)4.3
Macrophage colony-stimulating factor 1 receptorHomo sapiens (human)0.8417
Tyrosine-protein kinase LynHomo sapiens (human)0.22
ATP-dependent translocase ABCB1Homo sapiens (human)5.0229
Muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)0.4
Hepatocyte growth factor receptorHomo sapiens (human)0.0216
Platelet-derived growth factor receptor betaHomo sapiens (human)0.285
Dihydrofolate reductaseEscherichia coli K-120.372
Mast/stem cell growth factor receptor KitHomo sapiens (human)1.2682
Breakpoint cluster region proteinHomo sapiens (human)0.5032
Solute carrier family 2, facilitated glucose transporter member 4Mus musculus (house mouse)0.473
Dipeptidyl peptidase 4Rattus norvegicus (Norway rat)5
Ribosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)0.175
Platelet-derived growth factor receptor alphaHomo sapiens (human)0.1516
Thromboxane-A synthase Homo sapiens (human)0.198
Cyclin-dependent kinase 2Homo sapiens (human)3.318
Histamine H2 receptorHomo sapiens (human)1.963
Platelet-derived growth factor receptor alpha Mus musculus (house mouse)0.3
5-hydroxytryptamine receptor 2AHomo sapiens (human)1.891
Sodium-dependent serotonin transporterHomo sapiens (human)1.402
Receptor-type tyrosine-protein kinase FLT3Homo sapiens (human)0.131
Tyrosine-protein kinase ABL2Homo sapiens (human)0.156
Tyrosine-protein kinase SYKHomo sapiens (human)5
Serine/threonine-protein kinase PLK1Homo sapiens (human)4.3
Platelet-derived growth factor receptor betaRattus norvegicus (Norway rat)0.162
Epithelial discoidin domain-containing receptor 1Homo sapiens (human)0.2964
Discoidin domain-containing receptor 2Homo sapiens (human)0.457
Leucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)8.3
Multidrug and toxin extrusion protein 2Homo sapiens (human)1.625
Multidrug and toxin extrusion protein 1Homo sapiens (human)0.1467
Aurora kinase BHomo sapiens (human)4.3
Broad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)2.9096
Aurora kinase CHomo sapiens (human)4.3

Research

Studies (9)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (22.22)29.6817
2010's7 (77.78)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Atteridge, CE; Azimioara, MD; Benedetti, MG; Biggs, WH; Carter, TA; Ciceri, P; Edeen, PT; Fabian, MA; Floyd, M; Ford, JM; Galvin, M; Gerlach, JL; Grotzfeld, RM; Herrgard, S; Insko, DE; Insko, MA; Lai, AG; Lélias, JM; Lockhart, DJ; Mehta, SA; Milanov, ZV; Patel, HK; Treiber, DK; Velasco, AM; Wodicka, LM; Zarrinkar, PP1
Atteridge, CE; Campbell, BT; Chan, KW; Ciceri, P; Davis, MI; Edeen, PT; Faraoni, R; Floyd, M; Gallant, P; Herrgard, S; Hunt, JP; Karaman, MW; Lockhart, DJ; Milanov, ZV; Morrison, MJ; Pallares, G; Patel, HK; Pritchard, S; Treiber, DK; Wodicka, LM; Zarrinkar, PP1
Hajduk, PJ; Johnson, EF; Kifle, L; Merta, PJ; Metz, JT; Soni, NB1
Russu, WA; Shallal, HM1
Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP1
Al-Mazaideh, GM; Erdmann, F; Göllner, C; Rohe, A; Schmidt, M; Sippl, W; Wichapong, K1
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ1
Cahya, S; Cummins, DJ; Gao, C; Iversen, PW; Nicolaou, CA; Vieth, M; Wang, J; Watson, IA1
Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP1

Other Studies

9 other study(ies) available for vatalanib and imatinib

ArticleYear
A small molecule-kinase interaction map for clinical kinase inhibitors.
    Nature biotechnology, 2005, Volume: 23, Issue:3

    Topics: Benzamides; Drug Design; Escherichia coli; Escherichia coli Proteins; Imatinib Mesylate; Microchemistry; Pharmaceutical Preparations; Piperazines; Protein Binding; Protein Interaction Mapping; Protein Kinase Inhibitors; Pyrimidines

2005
A quantitative analysis of kinase inhibitor selectivity.
    Nature biotechnology, 2008, Volume: 26, Issue:1

    Topics: Binding Sites; Enzyme Activation; Humans; Phosphotransferases; Protein Binding; Protein Interaction Mapping; Protein Kinase Inhibitors; Proteome; Quantitative Structure-Activity Relationship

2008
Navigating the kinome.
    Nature chemical biology, 2011, Volume: 7, Issue:4

    Topics: Drug Design; Pharmacogenetics; Protein Kinases; Proteome; Systems Biology

2011
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.
    European journal of medicinal chemistry, 2011, Volume: 46, Issue:6

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Molecular Structure; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Stereoisomerism; Structure-Activity Relationship

2011
Comprehensive analysis of kinase inhibitor selectivity.
    Nature biotechnology, 2011, Oct-30, Volume: 29, Issue:11

    Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity

2011
Evaluation of potential Myt1 kinase inhibitors by TR-FRET based binding assay.
    European journal of medicinal chemistry, 2013, Volume: 61

    Topics: Dose-Response Relationship, Drug; Fluorescence Resonance Energy Transfer; Glycolipids; Humans; Membrane Proteins; Models, Molecular; Molecular Structure; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Structure-Activity Relationship

2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
    Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:12

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship

2012
Selectivity data: assessment, predictions, concordance, and implications.
    Journal of medicinal chemistry, 2013, Sep-12, Volume: 56, Issue:17

    Topics: Computer Simulation; Drug Discovery

2013
The target landscape of clinical kinase drugs.
    Science (New York, N.Y.), 2017, 12-01, Volume: 358, Issue:6367

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays

2017